Innocan Pharma Corp. Stock
€0.16
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Innocan Pharma Corp.
sharewise wants to provide you with the best news and tools for Innocan Pharma Corp., so we directly link to the best financial data sources.
Financials
News
Innocan Pharma Reports Second Quarter 2024 Results with Revenue Growth of over 2.8X to $8.6 Million
Innocan Pharma Reports Half Year 2024 Results with Revenue Growth of over 3.3X to $15.4 Million
Herzliya, Israel and Calgary, Alberta - August 12, 2024 - Innocan Pharma Corporation (CSE:
Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million
Herzliya, Israel and Calgary, Alberta - May 27, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company
Innocan Pharma Advances Liposomal CBD with Positive Response from FDA Following Successful Pre-IND Meeting
Herzliya, Israel and Calgary, Alberta - Sep 3, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options
Herzliya, Israel and Calgary, Alberta - August 29, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
Innocan Pharma’s Subsidiary BI Sky Global Successfully Completes FDA MoCRA Registration
Innocan Pharma Announces Private Placement
Herzliya, Israel and Calgary, Alberta - Aug 22, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the
Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center
Herzliya, Israel and Calgary, Alberta – July 26, 2024 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
Innocan Pharma Engages Pain Management Expert in Preparation for Upcoming FDA Meeting
Herzliya, Israel and Calgary, Alberta - July 2, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs
Herzliya, Israel and Calgary, Alberta - June 11, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain
The regulatory approval process with the U.S. Food and Drug Administration has commenced for Innocan’s LPT-CBD release technology, marking a key step in the advancement of non-opioid pain
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
Herzliya, Israel and Calgary, Alberta - May 09, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M
Herzliya, Israel and Calgary, Alberta – April 1, 2024 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.
Herzliya, Israel and Calgary, Alberta - March 25, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug